focus -WSS

focus

author：leisure time 2025-10-02 11:08:57 - browse：6

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

focus

WSS

Medicare proceeds with plan to claw back hospital funds

Thousands protest in Iraq for a second day over burning of Quran in Sweden

Readout LOUD podcast: ESMO highlights & Roivant's big deal

ADA: All diabetes patients should be screened for liver condition

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

DeepMind touts AlphaFold's new skills as protein folding AI models face off

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Bright Health sells Medicare Advantage business to Molina

Why do we get seasonal allergies?

State Dept. review finds Biden bears some blame for Afghanistan failures

Brazil's Jair Bolsonaro is barred from running for office until 2030

ChatGPT in medicine: STAT answers readers' burning questions

Inari Medical to buy amputation prevention company LimFlow

Walensky prepares to leave CDC — and Congress — behind

Supreme Court rules employers must be more accommodating of religious observance

Sports medicine is finally prioritizing gender equality

UnitedHealth wins $3.3 billion takeover of Amedisys

Wikipedia

Infant mortality in U.S. rose last year for first time in decades: CDC

Tuskegee Airman Raymond Cassagnol dies at 102

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Gene therapy’s promise and the high cost of hope

ADA: All diabetes patients should be screened for liver condition

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

focus

focus

hotspot

entertainment